Shares of Rezolute fell over 85 percent on December 11, after the company announced that its Phase 3 sunRIZE study in congenital hyperinsulinism failed to meet its primary or key secondary endpoints. The company had previously made optimistic statements about the strength of earlier data and the outlook for the program that may have misled investors. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.